Urinary Tumor Markers for Bladder Cancer
Defines Blue Cross Blue Shield Oklahoma reimbursement policy for urinary biomarkers used in diagnosis and surveillance of bladder cancer, and which indications are not reimbursable; applies to providers submitting claims to BCBS OK.
New policy established for urinary tumor markers for bladder cancer.
Coverage Criteria: Urinary Tumor Markers for Bladder Cancer
Potentially Reimbursable Indications
Covered when ALL of the following are met for the stated indications:
Per reimbursement information items 1a and 1b.
ImmunoCyt/uCyt — Covered Adjunct Use
Covered when used as adjunct in monitoring:
Per reimbursement information item 2.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.